Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Psychemedics

This article was originally published in The Tan Sheet

Executive Summary

Psychemedics: Shipping PDT-90 personal drug test to Walgreen's. The 2,200-store chain is the first to offer the test, which previously sold via a toll-free number. The test analyzes a hair sample up to 90 days after removal to determine illegal drug use, including cocaine, marijuana, opiates, PCP and methamphetamine. FDA is expected to publish a proposed rule on OTC drugs of abuse tests in the next several months ("The Tan Sheet" Feb. 10, p. 16). The products now are being marketed under an interim policy in which FDA said it would not take action against unapproved OTC drug tests as long as they meet basic quality criteria. In August 1995, FDA sent a warning letter to Psychemedics stating that the PDT-90 test was an unapproved medical device; the agency later withdrew the letter in exchange for the firm's dismissal of a lawsuit against FDA, Psychemedics said in a Securities & Exchange Commission filing...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086935

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel